GT Medical Technologies, Inc. articles
CURRENT STANDARD OF CARE FOR BRAIN TUMORS
The current initial standard of care for aggressive brain tumors—whether they are primary brain tumors (ie, tumors that originate in the brain), or metastatic tumors from cancers that started outside of the brain—is resection. After surgery, a follow-up treatment, also referred to as adjuvant treatment, is often recommended to help eliminate any residual traces of the tumor.1 In the case of brain tumors, more often
As we embark on 2020, I find myself reflecting on the incredible growth GT Medical Technologies has experienced during the past year. We are filled with optimism knowing that each milestone along our journey represents new hope for patients with brain tumors.
2019 SCIENTIFIC AND BUSINESS ACHIEVEMENTS
- Completing our $10 Million Series A financing for commercialization
- Publishing the meningioma data subset in the prestigious Journal of Neurosurgery
- Win
ABSTRACT
Patients with brain tumors face enormous challenges after diagnosis. Many of these challenges are amplified by issues related to access to care.1‒4 Studies suggest that patients with cancer who live farther from radiation treatment centers have poorer clinical outcomes. In addition, minorities are more likely to perceive longer travel distances as a barrier, which may cause them to forgo needed radiation treatments.1‒4 To address these challenges,